Gene · 762
CA4: carbonic anhydrase 4
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CA4: carbonic anhydrase 4. Genes, record 762. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/762
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P22748 | Carbonic anhydrase 4 | 312 | 10 | Ensembl, GeneID, HGNC |
Source UniProt
Patents48
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026517404 A | 2026-05-29 | 1 | P22748 | Espacenet |
| JP 2026515744 A | 2026-05-19 | 264 | P22748 | Espacenet |
| EP 4719460 A1 | 2026-04-08 | 1 | P22748 | Espacenet |
| EP 4713339 A2 | 2026-03-25 | 1 | P22748 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4029 | P22748 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 681 | P22748 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 681 | P22748 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4029 | P22748 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 11722 | P22748 | Espacenet |
| JP 2025508968 A | 2025-04-10 | 180 | P22748 | Espacenet |
1 to 10 of 48
See all 48 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ACETAZOLAMIDE | CHEMBL20 | Carbonic anhydrase IV inhibitor | INHIBITOR | ChEMBL |
| ACETAZOLAMIDE SODIUM | CHEMBL1200814 | Carbonic anhydrase IV inhibitor | INHIBITOR | ChEMBL |
| DICHLORPHENAMIDE | CHEMBL17 | Carbonic anhydrase IV inhibitor | INHIBITOR | ChEMBL |
| ETHOXZOLAMIDE | CHEMBL18 | Carbonic anhydrase inhibitor | INHIBITOR | ChEMBL |
| METHAZOLAMIDE | CHEMBL19 | Carbonic anhydrase IV inhibitor | INHIBITOR | ChEMBL |
| SULTHIAME | CHEMBL328560 | Carbonic anhydrase inhibitor | INHIBITOR | ChEMBL |
| TOPIRAMATE | CHEMBL220492 | Carbonic anhydrase IV inhibitor | INHIBITOR | ChEMBL |
Trials230
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07588750 | TOPIRAMATE | ClinicalTrials.gov | ||
| NCT07517068 | ACETAZOLAMIDE | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07469722 | ACETAZOLAMIDE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07384624 | TOPIRAMATE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07372040 | ACETAZOLAMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06981234 | ACETAZOLAMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06945848 | ACETAZOLAMIDE | ClinicalTrials.gov | ||
| NCT06919744 | ACETAZOLAMIDE | ClinicalTrials.gov | ||
| NCT06783166 | ACETAZOLAMIDE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06776432 | ACETAZOLAMIDE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 230
See all 230 trialsNIH grants1,287
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CA4 papers | Newest fiscal year |
|---|---|---|---|
| P30CA054174 | Mays Cancer Center at UT Health SA | 9 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 7 | 2025 |
| P30EY025580 | Multidisciplinary Investigations in Visual Science | 7 | 2025 |
| R01EY024605 | Choriocapillaris Protection and Replacement in AMD | 7 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| R01CA148706 | Targeting the colchicine binding site in tubulin for cancer therapy | 5 | 2025 |
| P01AG026276 | Antecedent Biomarkers for Alzheimer Disease: The Adult Children Study | 4 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 3 | 2025 |
| P30CA142543 | UT Southwestern Medical Center Simmons Comprehensive Cancer Center | 3 | 2025 |
| P30DK034987 | Center for Gastrointestinal Biology and Disease | 3 | 2025 |
1 to 10 of 1,287Source NIH's project files
See all 1,287 nih grantsPapers2,162
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genetic architecture of externalizing and internalizing traits in the general population and its link to psychiatric conditions and well-being: a multivariate approach. | Eur Neuropsychopharmacol | 2026 | 42679763 | PubTator, text mining | PubMed |
| Transcriptome-Based Six-Gene Fatty Acid Metabolism Signature for Prognosis and Predicted Immunotherapy Response in Lung Adenocarcinoma: Cross-Population Validation. | Genes (Basel) | 2026 | 42650107 | PubTator, text mining | PubMed |
| CA-IV-directed small-molecule shuttle enables targeted brain delivery of biologics. | Nat Chem Biol | 2026 | 42649418 | PubTator, text mining | PubMed |
| Structural Heterogeneity of TDP-43 Fragments in Alzheimer's Disease and Primary Age-Related Tauopathy by Artificial Intelligence (AI)-Based 3D Segmentation. | Neuropathol Appl Neurobiol | 2026 | 42576167 | PubTator, text mining | PubMed |
| SARS-CoV-2 nucleocapsid protein drives pulmonary injury by enhancing GRP75-dependent ER-mitochondria tethering and reprogramming of alveolar macrophages. | Life Sci | 2026 | 42570816 | PubTator, text mining | PubMed |
| Long-Term Blood Pressure Variability, Hippocampal Subfield Volume and Cognitive Decline: A Population-Based Prospective MRI Study. | J Magn Reson Imaging | 2026 | 42561035 | PubTator, text mining | PubMed |
| Identification of a Duplication in the RP17 Locus in an Individual With Pathogenic CEP290 Variants: Implications for RP17 Variant Classification. | Invest Ophthalmol Vis Sci | 2026 | 42545071 | PubTator, text mining | PubMed |
| Hippocampal volume and white matter impairments in patients with congenital adrenal hyperplasia. | J Clin Endocrinol Metab | 2026 | 42535568 | PubTator, text mining | PubMed |
| Carbonic anhydrases IV and XV. | Enzymes | 2026 | 42486554 | PubTator, text mining | PubMed |
| Comprehensive Spatial Transcriptomic Profiling of Cribriform, Intraductal, Atypical Intraductal Proliferation, and Ductal Adenocarcinoma of the Prostate. | Lab Invest | 2026 | 42468875 | PubTator, text mining | PubMed |
1 to 10 of 2,162
See all 2,162 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/762
GET https://conductscience.org/api/genes/v1/762/patents?page=2